Evithrom Market Report 2026

Evithrom Market Overview

• The Evithrom market growth in the historic period has been driven by high surgical blood loss risks, need for fast acting hemostasis • Market expansion is supported by growth in surgical interventions, rising accident and trauma rates • Growth Driver: Growing Surgical Procedures Drive Expansion Of The Evithrom Market • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Evithrom Market?

Evithrom is a topical hemostatic agent composed of human thrombin and fibrinogen, designed to control bleeding during surgical procedures. It is used in various surgeries, including cardiovascular and orthopedic procedures, to promote blood clot formation and prevent excessive bleeding. The main types of indications in evithrom are surgical hemostasis and trauma care. Surgical hemostasis refers to the techniques and measures used during surgical procedures to stop bleeding and achieve blood vessel closure. It was formulated through bovine thrombin, human thrombin, and recombinant thrombin, distributed through hospitals, clinics, and diagnostic centers, and online pharmacies.

What Is The Evithrom Market Growth Forecast?

The growth in the forecast period can be attributed to growth in surgical interventions, rising accident and trauma rates, expanding hospital infrastructure, innovation in thrombin formulations, increased focus on surgical safety. Major trends in the forecast period include growing use of topical hemostatic agents, rising demand in cardiovascular surgeries, expansion of trauma and emergency care, preference for rapid clot formation solutions, increased adoption of human thrombin products.

Global Evithrom Market Segmentation

1) By Indication: Surgical Hemostasis, Trauma Care 2) By Formulation: Bovine Thrombin, Human Thrombin, Recombinant Thrombin 3) By Distribution Channel: Hospitals, Clinics And Diagnostic Centers, Online Pharmacies

What Are The Drivers Of The Evithrom Market?

A growing number of surgical procedures is expected to propel the growth of the evithrom market going forward. Surgical procedures refer to medical operations or interventions that involve the physical alteration or manipulation of tissues and organs within the body. The growth in surgical procedures is primarily driven by advancements in medical technology, which make surgeries safer and more efficient, and by the rising prevalence of chronic diseases, which require more surgical interventions. Evithrom is used in surgical procedures to control bleeding by promoting clot formation and enhancing hemostasis, particularly in high-risk surgeries such as cardiovascular or orthopedic procedures. For instance, in June 2024, according to the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based non-profit organization, liposuction remained the most common surgical procedure in 2023, with over 2.2 million performed, while face and head procedures saw significant growth, rising by 19.6% to more than 6.5 million. Therefore, the growing number of surgical procedures is driving the growth of the evithrom industry. Rising personalized medicine is expected to propel the growth of the evithrom market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient, such as their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The rising personalized medicine is due to advancements in genomic technologies, increased understanding of molecular biology, growing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Evithrom, a human thrombin product, supports personalized medicine by enabling precise hemostatic management tailored to individual patient profiles, ensuring optimal control of bleeding during surgical procedures. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, In 2023, the US Food and Drug Administration (FDA) granted approval for 16 new personalized treatments for rare disease patients, marking a substantial increase from the six approvals in 2022. Therefore, rising personalized medicine drives the evithrom industry. The increasing prevalence of spinal-related injuries is anticipated to drive the growth of the evithrom market in the future. Spinal-related injuries refer to damage or trauma to the spinal cord, vertebrae, discs, or surrounding tissues caused by accidents, falls, diseases, or medical conditions. Spinal injuries are rising due to increased road traffic accidents and an aging population prone to conditions like osteoporosis, leading to higher fracture risks. Evithrom is used in spinal surgeries to control bleeding by promoting clot formation at the surgical site, helping manage blood loss during procedures such as spinal fusion or decompression. For instance, in October 2024, according to the Congressionally Directed Medical Research Programs, a US-based authentic platform for Clinical Services, an estimated 300,000 people are living with spinal cord injuries (SCI) in the U.S., with over 17,000 new cases reported annually, and the numbers continue to rise. Therefore, the growing occurrence of spinal-related injuries is driving the growth of the evithrom industry.

Key Players In The Global Evithrom Market

Major companies operating in the evithrom market are Johnson & Johnson Inc.

Regional Insights

North America was the largest region in the evithrom market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Evithrom Market?

The evithrom market consists of sales of products including albumin, immunoglobulins, prothrombin complex concentrates, C1 esterase inhibitors, and fibrin sealants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Evithrom Market Report 2026?

The evithrom market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the evithrom industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.